<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ramesh, Remya</style></author><author><style face="normal" font="default" size="100%">Shingare, Rahul D.</style></author><author><style face="normal" font="default" size="100%">Kumar, Vinod</style></author><author><style face="normal" font="default" size="100%">Anand, Amitesh</style></author><author><style face="normal" font="default" size="100%">Swetha, B.</style></author><author><style face="normal" font="default" size="100%">Veeraraghavan, Sridhar</style></author><author><style face="normal" font="default" size="100%">Viswanadha, Srikant</style></author><author><style face="normal" font="default" size="100%">Ummanni, Ramesh</style></author><author><style face="normal" font="default" size="100%">Gokhale, Rajesh S.</style></author><author><style face="normal" font="default" size="100%">Reddy, D. Srinivasa</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Repurposing of a drug scaffold: identification of novel sila analogues of rimonabant as potent antitubercular agents</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Medicinal Chemistry</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">OCT</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">122</style></volume><pages><style face="normal" font="default" size="100%">723-730</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The structural similarity between an MmpL3 inhibitor BM212, and a cannabinoid receptor modulator rimonabant, prompted us to investigate the anti-tubercular activity of rimonabant and its analogues. Further optimization, particularly through incorporation of silicon into the scaffold, resulted in new compounds with significant improvement in anti-tubercular activity against Mycobacterium tuberculosis (H37Rv). The sila analogue 18a was found to be the most potent antimycobacterial compound (MIC, 31 ng/mL) from this series with an excellent selectivity index. (C) 2016 Elsevier Masson SAS. All rights reserved.&lt;/p&gt;</style></abstract><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;</style></custom3><custom4><style face="normal" font="default" size="100%">3.902</style></custom4></record></records></xml>